Johnson & Johnson vs. Pfizer: Consistency vs. Volatility in Revenue
J&J's quarterly sales have climbed with few setbacks, while Pfizer's have swung between $13.7 billion and $17.8 billion over eight quarters.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.